Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
DTIL Precision Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: DTIL
Price (delayed)
$5.15
Market cap
$53.98M
P/E Ratio
4.9
Dividend/share
N/A
EPS
$1.05
Enterprise value
-$24.44M
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome
Highlights
DTIL's EPS has soared by 107% year-on-year
DTIL's debt is down by 3.9% YoY
The company's equity has surged by 199% YoY but it fell by 13% QoQ
Precision Biosciences's quick ratio has surged by 181% YoY but it has decreased by 30% QoQ
Key stats
What are the main financial stats of DTIL
Market
Valuations
Earnings
Shares outstanding
10.48M
Market cap
$53.98M
Enterprise value
-$24.44M
Price to earnings (P/E)
4.9
Price to book (P/B)
0.7
Price to sales (P/S)
0.51
EV/EBIT
-2.73
EV/EBITDA
-1.81
EV/Sales
-0.36
Revenue
$68.7M
Gross profit
$68.7M
Operating income
-$26.16M
Net income
$7.17M
EBIT
$8.95M
EBITDA
$13.53M
Free cash flow
-$58.64M
Per share
Balance sheet
Liquidity
EPS
$1.05
EPS diluted
$1.04
Free cash flow per share
-$8.58
Book value per share
$7.35
Revenue per share
$10.05
TBVPS
$19.87
Total assets
$136.39M
Total liabilities
$80M
Debt
$30.05M
Equity
$56.39M
Working capital
$80.01M
Debt to equity
0.53
Current ratio
6.34
Quick ratio
7.28
Net debt/EBITDA
-5.8
Margins
Efficiency
Dividend
EBITDA margin
19.7%
Gross margin
100%
Net margin
10.4%
Operating margin
-38.1%
Return on assets
4.5%
Return on equity
12.3%
Return on invested capital
27.3%
Return on capital employed
7.4%
Return on sales
13%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DTIL stock price
How has the Precision Biosciences stock price performed over time
Intraday
-0.58%
1 week
-9.97%
1 month
11.47%
1 year
-54.3%
YTD
35.17%
QTD
7.97%
Financial performance
How have Precision Biosciences's revenue and profit performed over time
Revenue
$68.7M
Gross profit
$68.7M
Operating income
-$26.16M
Net income
$7.17M
Gross margin
100%
Net margin
10.4%
The company's net income has surged by 112% YoY but it fell by 17% QoQ
DTIL's net margin has soared by 108% YoY but it is down by 10% QoQ
The operating margin has dropped by 76% since the previous quarter but it has soared by 58% year-on-year
DTIL's operating income has shrunk by 61% QoQ but it is up by 40% YoY
Price vs fundamentals
How does DTIL's price correlate with its fundamentals
Growth
What is Precision Biosciences's growth rate over time
Valuation
What is Precision Biosciences stock price valuation
P/E
4.9
P/B
0.7
P/S
0.51
EV/EBIT
-2.73
EV/EBITDA
-1.81
EV/Sales
-0.36
DTIL's EPS has soared by 107% year-on-year
The company's equity has surged by 199% YoY but it fell by 13% QoQ
DTIL's P/B is 81% below its 5-year quarterly average of 3.6 and 42% below its last 4 quarters average of 1.2
The P/S is 92% lower than the 5-year quarterly average of 6.0 and 36% lower than the last 4 quarters average of 0.8
Precision Biosciences's revenue has increased by 41% YoY but it has decreased by 9% from the previous quarter
Efficiency
How efficient is Precision Biosciences business performance
Precision Biosciences's ROA has soared by 113% YoY but it has decreased by 13% from the previous quarter
DTIL's ROS has soared by 111% year-on-year but it is down by 8% since the previous quarter
Precision Biosciences's return on equity has surged by 106% YoY but it has decreased by 30% QoQ
The return on invested capital has surged by 104% year-on-year but it has declined by 27% since the previous quarter
Dividends
What is DTIL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DTIL.
Financial health
How did Precision Biosciences financials performed over time
Precision Biosciences's total assets is 70% more than its total liabilities
Precision Biosciences's quick ratio has surged by 181% YoY but it has decreased by 30% QoQ
DTIL's current ratio has surged by 132% year-on-year but it is down by 31% since the previous quarter
DTIL's debt is 47% lower than its equity
The company's equity has surged by 199% YoY but it fell by 13% QoQ
The debt to equity has dropped by 68% year-on-year but it has increased by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.